Search News Archives
Exhibitions & Events
AFFiRiS Will Explore ProBioGen’s Human Artificial Lymph Node Technology for Vaccine Testing
AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans. Using the HuALN technology AFFiRiS anticipates accelerating the progression of its human vaccine candidates into clinical trials.
"We have been looking for a system like the Human Artificial Lymph Node for quite a long time and are excited by the possibilities the system offers to test our peptide vaccine candidates which are delivered by our proprietary AFFITOME® technology", commented Walter Schmidt, CEO of AFFiRiS.
"AFFiRiS with its cutting-edge technology in the vaccine field is an ideal partner to further underline the strengths of ProBioGen's HuALN technology. We are very much looking forward to this co-operation" said Michael Schlenk, CEO of ProBioGen.
About the Human Artificial Lymph Node Technology
HuALN read-outs include soluble as well as cellular biomarkers, notably monitoring the induced cytokine secretion profiles to characterize T-cell-mediated immune responses (e.g. shifts in the TH1/TH2 pathways) and antibodies secretion patterns (IgM, IgG). Harvesting the cells after bioreactor operation allows their functional testing and analysis of surface markers by flow cytometry. Together with plasma cell analysis (by ELISPOT, flow cytometry, and organoid-histology) humoral and cellular immune responses can be determined. For literature see e.g. Giese et al., J Biotechnol., 2010 "Immunological substance testing on human lymphatic micro-organoids in vitro".
About ProBioGen AG - www.probiogen.de
In addition to its CHO platform, ProBioGen has developed proprietary AGE1® producer cell lines, for safe and cost-efficient production of highly active glycoproteins, monoclonal antibodies and virus-based vaccines. ProBioGen employs a broad range of qualified cell-based assays, including its proprietary Human Artificial Lymph Node technology. All services and technologies are embedded in a total quality management system, compliant with international ISO and GMP standards. ProBioGen was founded in 1994 and is located in Berlin, Germany.
About AFFiRiS AG - www.affiris.com